Extension Study of Semapimod 60 mg IV x 3 Days

Summary

Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study. The safety of multiple courses of semapimod is to be determined by the incidence of clinical and laboratory adverse events.

Timeline

Start

2003-07

Primary completion

2006-06

Completion

2006-06

Drugs

Indications